JIGAR SEROZI: ETIOLOGIYASI, KLINIK KECHISHI VA ZAMONAVIY DAVOLASH YONDASHUVLARI
Abstract
Jigar serozi — jigar to‘qimalarining surunkali zararlanishi va fibroz jarayoni tufayli organning tuzilishi hamda faoliyatining chuqur buzilishi bilan tavsiflanadigan og‘ir kasallikdir. U ko‘pincha virusli gepatitlar, uzoq muddatli spirtli ichimlik iste’moli, metabolik sindrom va yog‘li jigar kasalliklari, shuningdek, autoimmun jarayonlar natijasida yuzaga keladi. Seroz dastlab yashirin kechishi mumkin, biroq vaqt o‘tishi bilan asits, jigar ensefalopatiyasi, varikoz qon ketishi va jigar saratoni kabi xavfli asoratlarni keltirib chiqaradi. Kasallikni tashxislashda laborator tahlillar, ultratovush tekshiruvi, elastografiya, biopsiya hamda zamonaviy mashina o‘qitish texnologiyalaridan foydalanilmoqda. Davolashda sababchi omilni bartaraf etish, asoratlarni kamaytirish va hayot sifatini yaxshilash asosiy maqsad hisoblanadi. So‘nggi tadqiqotlar immun hujayra terapiyasi, antifibrotik dorilar, RNA asosidagi innovatsion usullar va jigar transplantatsiyasi serozi bilan kurashishda istiqbolli yo‘nalishlar ekanini ko‘rsatmoqda. Shuningdek, profilaktika choralariga rioya qilish — alkogoldan voz kechish, gepatitga qarshi vaksina, sog‘lom turmush tarzini shakllantirish kasallikning oldini olishda muhim ahamiyatga ega.
References
1. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–171. doi:10.1016/j.jhep.2018.09.014
2. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol. 2021;75(3):659–689.
3. Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ. 2018;362:k2817.
4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357.
5. Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Castille JM. Early detection of liver fibrosis progression by repeated biomarkers (FibroTest, ActiTest). Hepatology. 2020;71(1):24–35.
6. Jalan R, Saliba F, Pavesi M, Amorós A, Moreau R, Ginès P, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038–1047.
7. Bernal W, Wendon J. Acute-on-chronic liver failure. N Engl J Med. 2013;369:2525–2534.
8. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209.
9. Schmidt C, et al. Immune cell-based therapies for liver cirrhosis: from bench to bedside. Front Immunol. 2021;12:643. doi:10.3389/fimmu.2021.00643
10. Arroyo V, Moreau R, Jalan R, Ginès P. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. J Hepatol. 2015;62(1 Suppl):S131–S143.
